Wolters Kluwer CCH® Tagetik Intelligent Platform honored in 2025 Globee® Awards for Artificial Intelligence
NEW YORK--(BUSINESS WIRE)--Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that its AI-powered CCH® Tagetik Intelligent Platform has been named as the Bronze Globee® Winner in the Best AI-based Digital Transformation Solution category of the 2025 Globee® Awards for Artificial Intelligence.
The AI-powered CCH® Tagetik Intelligent Platform digitally transforms the efficiency, accuracy, and strategic ability of the Office of the CFO. Its state-of-the-art AI and GenAI functionality empowers finance professionals to democratize access to meaningful financial data, manage and control massive datasets with unprecedented speed and automation, unlock hidden insights and expedite decision making.
Karen Abramson, CEO of Wolters Kluwer Corporate Performance & ESG, said: 'Wolters Kluwer is honored to be recognized for the CCH® Tagetik Intelligent Platform in the 2025 Globee® Awards for Artificial Intelligence. Our AI-powered platform empowers CFOs to unlock insights from their data, enabling faster, more strategic decision-making. We remain committed to product excellence and innovation, anticipating market trends and delivering solutions that meet the evolving needs of CFOs.'
The Globee® Awards for Artificial Intelligence recognize exceptional individuals, teams, products, and organizations advancing the field of AI. This program celebrates innovation, practical implementation, and breakthrough achievements across AI technologies, tools, and applications. From machine learning and natural language processing to generative AI and ethical AI solutions, these awards highlight those setting new standards in transforming industries, enhancing user experiences, and solving real-world problems through artificial intelligence.
This award win was announced following the launch of the AI-powered CCH Tagetik Intelligent Platform in May 2024. The platform enables global finance leaders to automate all financial processes, including financial close and consolidation, extended planning and analysis, ESG and regulatory reporting, corporate tax, statutory and management reporting, integrated disclosure,and intelligent analytics.
Corporate Performance Management (CPM) business unit is part of the Wolters Kluwer Corporate Performance & ESG (CP & ESG) division. The division is the world's leading provider of integrated software solutions for EHS, ESG, Corporate Performance Management and Audit and Assurance. Through innovative technology and unique expertise, Wolters Kluwer CP & ESG enables business leaders to make informed, strategic decisions driving transformation, performance and risk management for a sustainable and resilient world.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Upturn
6 hours ago
- Business Upturn
Infosys inaugurates new Development Center at GIFT City to boost BFSI Tech services
Infosys (NSE, BSE, NYSE: INFY), a global leader in digital services and consulting, has inaugurated its new Development Center (DC) at Gujarat International Finance Tec-City (GIFT City), Gandhinagar. The newly launched facility is designed to support over 1,000 employees operating in a hybrid work model. The center will serve as a strategic TechFin hub, focusing on delivering advanced digital solutions to global Banking, Financial Services, and Insurance (BFSI) clients. Key service areas include digital banking, regulatory compliance, capital markets, trade finance, cards and payments, and risk management. Infosys will harness cutting-edge technologies such as Artificial Intelligence (AI), Generative AI (Gen AI), cloud, APIs, blockchain, and cybersecurity to provide seamless cross-border digital services and enhance client engagement. The Development Center was inaugurated by the Hon'ble Chief Minister of Gujarat, Shri Bhupendrabhai Patel. Infosys CFO Mr. Jayesh Sanghrajka, Senior Vice Presidents Mr. Niladri Prasad Mishra and Mr. Rajneesh Malviya, along with senior government officials, were present at the event. Aligned with Infosys' ESG (Environmental, Social, and Governance) goals, the facility integrates sustainable design features including energy efficiency, water conservation, and smart operational systems. The workplace also supports collaboration, productivity, and innovation through a future-ready hybrid office model. This initiative reinforces Infosys' commitment to strengthening India's role as a global financial technology hub and driving innovation in the BFSI sector. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 hours ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
